Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nandrolone Decanoate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.60 |
| ▸ | SHBG | P04278 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | PGR | P06401 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nandrolone Decanoate SCHEMBL6151508 | 1.00 | MAPT (1.00) | MAPTLMNAARSERPINA6ALDH1A1 | |
| SCHEMBL3803109 | 1.00 | MAPT (1.00) | MAPTLMNAARSERPINA6ALDH1A1 | |
| SCHEMBL635908 | 1.00 | MAPT (1.00) | MAPTLMNAARSERPINA6ALDH1A1 | |
| SCHEMBL11593159 | 1.00 | MAPT (1.00) | MAPTLMNAARSERPINA6ALDH1A1 | |
| SCHEMBL14568852 | 1.00 | MAPT (1.00) | MAPTLMNAARSERPINA6ALDH1A1 | |
| Nandrolone Decanoate SCHEMBL16107220 | 1.00 | MAPT (1.00) | MAPTLMNAARSERPINA6ALDH1A1 | |
| SCHEMBL11351978 | 1.00 | MAPT (1.00) | MAPTLMNAARSERPINA6ALDH1A1 | |
| Nandrolone Decanoate SCHEMBL10710160 | 1.00 | MAPT (1.00) | MAPTLMNAARSERPINA6ALDH1A1 | |
| SCHEMBL3850364 | 1.00 | MAPT (1.00) | MAPTLMNAARSERPINA6ALDH1A1 | |
| Nandrolone Decanoate SCHEMBL30692744 | 1.00 | MAPT (1.00) | MAPTLMNAARSERPINA6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180071313-A1 | DRY EYE THERAPEUTIC AGENT COMPRISING NANDROLONE OR ESTER THEREOF OR METHENOLONE OR ESTER THEREOF AS AN ACTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2018-03-15 | — | — | US | disclosed |
| EP-3278804-A1 | DRY EYE THERAPEUTIC AGENT HAVING AS ACTIVE INGREDIENT NANDROLONE OR ESTER THEREOF OR METHENOLONE OR ESTER THEREOF | Santen Pharmaceutical Co., Ltd. (JP) | 2018-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071313-A1 | DRY EYE THERAPEUTIC AGENT COMPRISING NANDROLONE OR ESTER THEREOF OR METHENOLONE OR ESTER THEREOF AS AN ACTIVE INGREDIENT | ALOX15, MME, ELANE | AR 3431/4885MAPT 4269/4885LMNA 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.